Open AccessCognitive effects with rivastigmine augmentation of risperidone: A 12-month, randomized, double-blind, placebo-controlled study in schizophrenia
Author(s) -
Prawin Kumar,
Seema P Mohemmedali,
P K Anish,
Chittaranjan Andrade
Publication year - 2017
Publication title -
indian journal of psychiatry/indian journal of psychiatry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.485
H-Index - 34
eISSN - 1998-3794
pISSN - 0019-5545
DOI - 10.4103/psychiatry.indianjpsychiatry_133_16
Subject(s) - rivastigmine , risperidone , schizophrenia (object oriented programming) , placebo , psychology , positive and negative syndrome scale , psychomotor learning , cognition , clinical global impression , medicine , randomized controlled trial , psychiatry , psychosis , donepezil , dementia , alternative medicine , disease , pathology
An important challenge in schizophrenia therapeutics is to develop an efficacious treatment for cognitive impairment. Acetylcholinesterase inhibitors, such as rivastigmine, have been studied for improving cognitive performance in these patients.